Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better ...

UB researchers have published the first longitudinal studies of paramagnetic rim lesions, an indicator of brain inflammation in MS.

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ...

The main external factors causing drug resistance are tumor immune microenvironment components, such as myelosuppressive cell (MDSC), regulatory T cell (Treg), M2 macrophages, and immunosuppressive ...